scholarly journals Stability over Time of Serum Antibody Levels to Human Papillomavirus Type 16

1998 ◽  
Vol 177 (6) ◽  
pp. 1710-1714 ◽  
Author(s):  
Veronika af Geijersstam ◽  
Mari Kibur ◽  
Zhaohui Wang ◽  
Pentti Koskela ◽  
Eero Pukka la ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Serum Antibody ◽  
Human Papillomavirus Type 16 ◽  
Antibody Levels ◽  
Over Time

scholarly journals Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies

2007 ◽  
Vol 15 (1) ◽  
pp. 60-64 ◽  
Author(s):  
Troy J. Kemp ◽  
Allan Hildesheim ◽  
Roni T. Falk ◽  
John T. Schiller ◽  
Douglas R. Lowy ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Neutralization Assay ◽  
Serum Samples ◽  
Neutralizing Activity ◽  
Human Papillomavirus Type 16 ◽  
Vaccine Trials ◽  
Specimen Collection ◽  
Virus Like Particle ◽  
Protection Against Infection ◽  
Antibody Levels

ABSTRACT Immunogenicity evaluations in human papillomavirus (HPV) vaccine trials have relied on serological samples, yet cervical antibodies are likely to be most relevant for protection against infection. In order to assess functional antibody levels at the cervix, the secreted-alkaline-phosphatase neutralization assay (SEAPNA) was used to measure HPV-neutralizing activity. We assessed the variability of the SEAPNA with serum samples after vaccination with an HPV type 16 (HPV16) L1 virus-like particle vaccine and whether the SEAPNA can be used to monitor neutralizing activity at the cervix. The SEAPNA has an overall coefficient of variation of 29.3%. Recovery from ophthalmic sponges was assessed by spiking V5 (mouse anti-HPV16) antibody onto and extracting it from sterile Merocel and Ultracell sponges and sponges used to collect specimens from participants. V5 recovery from sterile Merocel sponges was complete, yet that from Ultracell sponges was null. The mean V5 recoveries from participant Ultracell and Merocel sponges were 61.2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix.

Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus Species

2006 ◽  
Vol 66 (23) ◽  
pp. 11120-11124 ◽  
Author(s):  
Ratish Gambhira ◽  
Patti E. Gravitt ◽  
Ioannis Bossis ◽  
Peter L. Stern ◽  
Raphael P. Viscidi ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Fusion Protein ◽  
Healthy Volunteers ◽  
Serum Antibody ◽  
Human Papillomavirus Type 16

scholarly journals Comparison of Different Assays To Assess Human Papillomavirus (HPV) Type 16- and 18-Specific Antibodies after HPV Infection and Vaccination

2013 ◽  
Vol 20 (8) ◽  
pp. 1329-1332 ◽  
Author(s):  
Mirte Scherpenisse ◽  
Rutger M. Schepp ◽  
Madelief Mollers ◽  
Sofie H. Mooij ◽  
Chris J. L. M. Meijer ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Serum Antibody ◽  
Hpv Infection ◽  
Serum Samples ◽  
Specific Antibodies ◽  
Multiplex Immunoassay ◽  
Specific Serum ◽  
Virus Like Particle ◽  
Large Panel ◽  
Antibody Levels

ABSTRACTWe compared the measurement of human papillomavirus (HPV)-specific serum antibody levels with the virus-like-particle multiplex immunoassay (VLP-MIA), competitive Luminex immunoassay (cLIA), and glutathioneS-transferase (GST) L1-based MIA. Using a large panel of serum samples, these assays showed mutually good correlations for both naturally induced and vaccine-derived HPV-specific antibody levels. However, an adaptation of the GST L1-based MIA resulted in an improved correlation with both cLIA and VLP-MIA.

scholarly journals Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommon

2010 ◽  
Vol 91 (8) ◽  
pp. 2068-2072 ◽  
Author(s):  
Martin Steinau ◽  
David C. Swan ◽  
Juanita M. Onyekwuluje ◽  
John T. Brooks ◽  
Claudia Vellozzi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Papillomavirus ◽  
Anatomical Site ◽  
Hpv 16 ◽  
Cervical Sample ◽  
Human Papillomavirus Type 16 ◽  
Immunodeficiency Virus ◽  
Serial Samples ◽  
Study Participants ◽  
Over Time

Human papillomavirus type 16 (HPV-16) genotype variants have been the subject of several investigations, but study participants have rarely been sampled more than once. In this study, among a cohort of human immunodeficiency virus (HIV)-infected adults, HPV-16 variants were investigated in samples collected concurrently from the anus and cervix, as well as in serial samples collected from the same anatomical site at 12-month intervals. HPV-16 variants in stored extracts of cervical and anal samples were determined from subjects with multiple visits and at least one sample positive for HPV-16. Seven polymorphic nucleotide positions within the E6 region were analysed by pyrosequencing to determine genotype variants. Of 364 samples examined, 176 anal and 39 cervical swabs from 84 different subjects yielded unequivocal sequences of eight major HPV-16 variants. Eight samples contained probable novel HPV-16 variants and in one sample two variants were detected. In eight out of 29 (27.6 %) anal–cervical sample pairs positive for HPV-16, discordant variants were found. From 57 anal and nine cervical sample series of HPV-16-positive samples, a change in HPV-16 variant status over time was seen in nine (13.6 %) instances (seven anal and two cervical) from eight different participants. Changes in HPV-16 variants in HIV-infected adults were seen most frequently when different anatomical sites were sampled, but were also observed over time.

scholarly journals Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients

1995 ◽  
Vol 86 (1) ◽  
pp. 28-34 ◽  
Author(s):  
Takuma Fujii ◽  
Youko Matsushima ◽  
Masazumi Yajima ◽  
Takashi Sugimura ◽  
Masaaki Terada
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Patients ◽  
Serum Antibody ◽  
Human Papillomavirus Type 16
Sign in / Sign up

Export Citation Format

Share Document